MAIA Biotechnology, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
At-The-Market Financing
Issuance of common shares in connection with intial public offering, issuance cost	$ 658,801	$ 428,396
Follow-on Offering
Issuance of common shares in connection with intial public offering, issuance cost		1,593,016
Private Placement Offering
Issuance of common shares in connection with intial public offering, issuance cost	$ 136,456
Direct Offering
Issuance of common shares in connection with intial public offering, issuance cost		$ 702,202